Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a routine blood test flag a dangerous pregnancy complication?

NCT ID NCT07826247

Diagnosis Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Placenta accreta spectrum is a serious pregnancy complication where the placenta grows too deeply into the uterus, risking severe bleeding during delivery. Doctors usually rely on ultrasound to detect it, but ultrasound accuracy varies. This study checks whether simple blood tests taken on hospital admission can help predict which mothers with placenta previa and a prior cesarean delivery will develop the condition. Researchers compare blood test results with the actual diagnosis confirmed at delivery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the blood markers prove reliable, doctors could use a routine blood test alongside ultrasound to flag high-risk pregnancies earlier and plan safer deliveries.
What could go wrong
This is an observational study, so it can only show whether markers correlate with placenta accreta, not whether acting on them improves outcomes. The findings may not hold up in other hospitals or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 130 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of pregnant women aged 18 to 40 years presenting to the Women's Health Hospital at Assiut University. Eligible participants must have a singleton pregnancy at a gestational age greater than 28 weeks, a diagnosis of placenta previa confirmed by ultrasound, a history of previous cesarean delivery, and be hemodynamically stable upon admission. Patients will be excluded if they present with intrauterine fetal demise (IUFD), intrauterine growth restriction (IUGR), premature rupture of membranes (PROM), chorioamnionitis, known blood diseases or bleeding tendencies, hypertension, or diabetes mellitus.

Ages

18 to 40 years

Sex

Female participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: 18-40 years * Placenta previa diagnosed by ultrasound * Singleton pregnancy * Gestational age \>28 weeks * Previous cesarean delivery * Hemodynamically stable on admission Exclusion Criteria: * Intrauterine fetal demise (IUFD) * Intrauterine growth restriction (IUGR) * Premature rupture of membranes (PROM) * Chorioamnionitis * Patients with known blood disease or bleeding tendency * Hypertension (HTN) * Diabetes mellitus (DM)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Placenta accreta spectrum are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

placenta accreta placenta praevia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Placenta accreta spectrum Placenta previa

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.